JAL16 Antibody

What is JL16 antibody and what virus does it target?

JL16 is a human monoclonal antibody isolated from the B cells of ANDV convalescent HCPS survivors from Chile. It specifically targets Andes virus (ANDV), a member of the Hantavirus genus that causes Hantavirus Cardiopulmonary Syndrome (HCPS), a severe and often fatal respiratory disease . The antibody was identified through screening of multiple ANDV-specific memory B cell clones from survivors and shows strong binding to the viral glycoprotein .

What is the genetic composition of JL16 antibody?

JL16 antibody displays 91.12% germline identity for the heavy chain and 95.45% germline identity for the light chain. Specifically, the heavy chain belongs to the IGHV3-74 family, with its closest V gene match to HV3-7403, closest D gene match to HD3-302, and closest J gene match to J301. The light chain belongs to the IGV1-40 family, with V gene match closest to LV1-4001 and J gene match closest to LJ2*01 .

How does JL16 antibody neutralize ANDV infection?

JL16 antibody neutralizes ANDV infection by binding to the viral glycoprotein (ANDV-GP) expressed on the surface of infected cells and viral particles. This binding prevents the virus from attaching to and entering host cells, effectively blocking the initial stage of viral infection. In vitro studies demonstrated that JL16 can neutralize both ANDV pseudovirions and live ANDV in focus reduction neutralization tests (FRNT80), with an IC50 of 6.60 μg/ml in pseudovirus assays and an FRNT80 of 15.35 μg/ml against live virus .

How does JL16 compare with other anti-ANDV antibodies?

When compared to another monoclonal antibody (MIB22) isolated from the same patient, JL16 shows different properties:

JL16 shows a slower dissociation rate than MIB22, suggesting higher relative affinity, despite MIB22 having a better neutralization capacity .

What mechanisms explain JL16's efficacy in post-exposure treatment of ANDV infection?

JL16's efficacy as a post-exposure treatment stems from multiple factors. First, its high binding affinity and notably slow dissociation rate (80% of antibody remained bound after 120 minutes, compared to 54% for MIB22) allow it to maintain persistent neutralization of viral particles . Second, JL16 recognizes a distinct epitope on ANDV-GP that appears to be critical for viral entry. The antibody has demonstrated complete protection in Syrian hamster models when administered after ANDV exposure, suggesting rapid viral clearance or inhibition of viral dissemination. Notably, survivors treated with JL16 showed no detectable ANDV RNA in lung tissue at 36 days post-challenge, whereas MIB22-treated animals still harbored residual viral RNA .

How can researchers optimize antibody engineering approaches for JL16 based on its germline identity?

Engineering approaches for JL16 can leverage its relatively high germline identity (91.12% for heavy chain and 95.45% for light chain) to minimize potential immunogenicity. Researchers should:

• Identify critical somatic hypermutations (SHM) that contribute to JL16's binding and neutralization capabilities through alanine scanning mutagenesis

• Consider reverting non-critical mutations to germline sequences to further increase germline identity

• Apply computational structural modeling to optimize CDR conformations while maintaining epitope recognition

• Engineer Fc modifications (like LALA mutations as demonstrated with STI-9167 antibody) to eliminate potential antibody-dependent enhancement effects

• Assess the impact of different IgG isotypes on effector functions and half-life

This approach parallels strategies used for minimally mutated HIV broadly neutralizing antibodies, which aim to facilitate vaccine design by reducing rare antibody features while maintaining broad neutralization capacity .

What are the optimal methods for assessing JL16's neutralization potential against emerging ANDV variants?

For comprehensive assessment of JL16's neutralization potential against emerging ANDV variants, researchers should implement a multi-tiered approach:

• Pseudovirus neutralization assays incorporating glycoprotein variants of concern

• Focus reduction neutralization tests (FRNT80) with live virus isolates

• Competitive binding assays with quantum dot-labeled antibodies to determine epitope conservation

• Surface plasmon resonance (SPR) analysis of binding kinetics to variant glycoproteins

• Structural analysis of antibody-glycoprotein complexes using cryo-electron microscopy

• In vivo protection studies in the Syrian hamster model using variant ANDV challenges

This systematic evaluation should be performed in biosafety level 3 (BSL-3) or BSL-4 facilities due to the pathogenic nature of ANDV .

What considerations should be taken into account when developing JL16 and MIB22 as a combination therapy?

When developing JL16 and MIB22 as combination therapy, researchers should address:

• Epitope complementarity: Competition binding studies have shown that JL16 and MIB22 recognize distinct epitopes on ANDV-GP, allowing simultaneous binding and potentially synergistic neutralization .

• Optimal dosing ratio: Determine whether equal concentrations (1:1) or differential ratios better leverage their distinct neutralization profiles and dissociation kinetics.

• Formulation stability: Assess antibody stability, aggregation tendencies, and compatibility in combination formulations.

• Potential antagonism: Although initial studies show no antagonistic binding, comprehensive tests should evaluate whether combination affects individual neutralization potency.

• Resistance barrier: Combination therapy may raise the genetic barrier to viral escape mutations by targeting multiple epitopes simultaneously.

• Administration timing: Evaluate whether sequential or simultaneous administration provides optimal protection in animal models.

What are the most reliable methods for producing and purifying JL16 antibody for research purposes?

For reliable production and purification of JL16 antibody:

• Expression system selection: Transiently transfect HEK293 cells with plasmids encoding heavy and light chains for small-scale production, or develop stable CHO cell lines for larger quantities.

• Purification protocol:

  • Harvest cell culture supernatant after 4-7 days

  • Clarify by centrifugation (10,000g for 30 minutes)

  • Purify using Protein A affinity chromatography

  • Perform size-exclusion chromatography to remove aggregates

  • Concentrate using tangential flow filtration

  • Sterile filter through 0.22μm membrane

• Quality control measures:

  • SDS-PAGE and Western blot to confirm purity and identity

  • ELISA binding assay against ANDV-GP

  • SPR to verify binding kinetics

  • Functional neutralization assay using pseudovirus system

• Storage conditions: Store at 4°C for short-term use or -80°C (with cryoprotectants) for long-term storage to maintain neutralization activity .

How can researchers accurately assess the binding kinetics of JL16 to ANDV glycoprotein?

To accurately assess binding kinetics of JL16 to ANDV glycoprotein:

• Surface Plasmon Resonance (SPR):

  • Immobilize purified ANDV-GP on a CM5 sensor chip

  • Flow JL16 at concentrations ranging from 0.1-100 nM

  • Determine association (kon) and dissociation (koff) rates

  • Calculate affinity constant (KD = koff/kon)

• Bio-Layer Interferometry (BLI):

  • Immobilize JL16 on protein A biosensors

  • Expose to varying concentrations of ANDV-GP

  • Monitor real-time binding kinetics

• Flow cytometry-based dissociation assay:

  • Transfect 293T cells with ANDV-GP

  • Incubate with saturating JL16 concentrations

  • Measure antibody retention over time (37°C)

  • Calculate dissociation half-life

• Isothermal Titration Calorimetry (ITC):

  • Directly measure thermodynamic parameters

  • Determine binding stoichiometry and energetics

The flow cytometry-based dissociation assay has been specifically validated for JL16, showing that 80% of bound antibody remains after 120 minutes at 37°C, compared to 54% for MIB22 and 68% for polyclonal IgG .

What in vivo models are most appropriate for testing JL16's therapeutic efficacy?

The Syrian hamster model is the most appropriate in vivo model for testing JL16's therapeutic efficacy against ANDV infection. This model recapitulates many hallmarks of human ANDV-induced HCPS, including:

• Disease progression: Development of lethargy and pulmonary edema, with nearly uniform lethality, mimicking human disease course.

• Experimental design considerations:

  • Challenge dose: 200 FFU of ANDV administered intranasally

  • Treatment timing: Antibody administration ideally 3-5 days post-infection to assess post-exposure efficacy

  • Dosing: 10 mg/kg intraperitoneal administration is effective

  • Control groups: Include isotype antibody controls and untreated infected controls

• Endpoints and monitoring:

  • Survival rate and time to death

  • Clinical signs scoring

  • Quantitative RT-PCR for viral RNA in tissues

  • Histopathological examination of lungs

  • Anti-N antibody seroconversion by ELISA to confirm infection

• Safety considerations: All experiments must be conducted in appropriate BSL-4 containment facilities due to the highly pathogenic nature of ANDV .

How can epitope mapping be performed to precisely determine JL16's binding site on ANDV glycoprotein?

For precise epitope mapping of JL16's binding site on ANDV glycoprotein:

• X-ray crystallography:

  • Generate Fab fragments of JL16

  • Co-crystallize with purified ANDV-GP or its receptor-binding domain

  • Solve structure at high resolution (≤2.5Å)

  • Identify interacting amino acid residues

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS):

  • Compare deuterium uptake of ANDV-GP alone versus JL16-bound

  • Map regions with reduced exchange rates indicating protection by antibody binding

• Alanine scanning mutagenesis:

  • Generate ANDV-GP variants with single alanine substitutions

  • Test JL16 binding to each variant

  • Identify critical contact residues where mutations abolish binding

• Cryo-electron microscopy (Cryo-EM):

  • Visualize JL16-ANDV-GP complexes

  • Generate 3D reconstructions at sub-nanometer resolution

  • Map binding interface

• Competition assays:

  • Use quantum dot-labeled antibodies (as demonstrated with JL16-Qdot-800)

  • Assess competitive binding with other antibodies of known epitopes

  • The non-competitive binding between JL16 and MIB22 suggests they recognize different epitope regions

How can JL16 be utilized in diagnostic applications for ANDV infection?

JL16 can be utilized in several diagnostic applications for ANDV infection:

• Antigen detection assays:

  • Develop sandwich ELISA using JL16 as a capture antibody

  • Create rapid lateral flow assays for point-of-care testing

  • Develop fluorescent antibody-based detection in tissue samples

• Immunofluorescence assay development:

  • JL16 has been validated for confocal microscopy detection of ANDV-GP on cell surfaces

  • Can be used to confirm ANDV infection in tissue or cell culture specimens

• Virus capture and concentration:

  • Conjugate JL16 to magnetic beads for virus concentration from clinical samples

  • Enhance PCR detection sensitivity through antibody-mediated viral enrichment

• Quantitative viral detection:

  • Develop ELISA-based viral quantification using JL16's high affinity for ANDV

  • JL16 showed strong binding to ANDV pseudovirus particles, with 2.8-fold higher detection at 0.1 μg/ml compared to polyclonal IgG

• Competition-based serological assays:

  • Develop assays to measure patient antibody responses by competition with JL16

These applications leverage JL16's high affinity and slow dissociation rate, which contribute to sensitive and specific detection of ANDV.

What considerations are important when evaluating potential escape mutations against JL16?

When evaluating potential escape mutations against JL16:

• Systematic mutation library generation:

  • Create a comprehensive library of ANDV-GP mutants using site-directed mutagenesis

  • Focus on surface-exposed residues in regions likely to interact with JL16

  • Include naturally occurring polymorphisms from different ANDV isolates

• Neutralization escape assay design:

  • Perform sequential passaging of ANDV in presence of sub-neutralizing JL16 concentrations

  • Sequence emergent resistant viral populations

  • Validate identified mutations through reverse genetics

• Structure-guided analysis:

  • Use computational structural modeling to predict epitope residues

  • Prioritize mutations at predicted antibody-antigen interface

• Combinatorial resistance assessment:

  • Evaluate if JL16-escape mutants remain susceptible to MIB22 neutralization

  • Assess escape frequency when both antibodies are used in combination

  • The demonstrated non-competitive binding between JL16 and MIB22 suggests a combination approach may minimize escape

• Fitness cost evaluation:

  • Assess replication capacity of escape mutants

  • Determine stability of mutations in absence of antibody pressure

Understanding escape mutations can inform combination antibody therapy design and predict therapeutic efficacy against naturally occurring ANDV variants.

How does the route of administration affect JL16's therapeutic efficacy?

The route of administration can significantly impact JL16's therapeutic efficacy. Though specific studies on JL16 administration routes aren't detailed in the search results, parallels can be drawn from similar therapeutic antibody research:

• Intravenous administration:

  • Provides immediate systemic biodistribution

  • Achieves high serum concentrations rapidly

  • May be optimal for disseminated infection

  • The standard route used in JL16 protective efficacy studies in Syrian hamsters

• Intraperitoneal administration:

  • Used successfully in animal studies with JL16

  • Slower absorption than intravenous but still achieves systemic distribution

  • Practical for animal studies but less relevant for human application

• Intranasal administration:

  • Directly targets the respiratory tract, the primary site of ANDV infection

  • May provide localized protection with lower doses

  • Similar antibodies for respiratory viruses (like STI-9167 for SARS-CoV-2) have shown that intranasal delivery can be as effective as intravenous administration in animal models

  • Could increase respiratory tract bioavailability while using smaller antibody quantities

• Factors affecting route selection:

  • Disease stage (early localized vs. systemic infection)

  • Therapeutic objective (prevention vs. treatment)

  • Antibody formulation stability

  • Patient condition and compliance considerations

Researchers should conduct comparative pharmacokinetic studies of different administration routes to optimize therapeutic protocols for JL16.

What are the challenges in transitioning JL16 from preclinical research to clinical applications?

Transitioning JL16 from preclinical research to clinical applications faces several challenges:

• Manufacturing scale-up and optimization:

  • Develop stable cell lines with high antibody expression

  • Optimize purification processes for clinical-grade material

  • Ensure batch-to-batch consistency in functional characteristics

  • Implement quality control measures compliant with regulatory standards

• Formulation development:

  • Determine optimal buffer conditions for long-term stability

  • Develop lyophilized formulations if necessary for field use

  • Assess compatibility with delivery devices for various administration routes

• Preclinical safety assessment:

  • Conduct comprehensive toxicology studies in relevant animal models

  • Evaluate potential for antibody-dependent enhancement (ADE)

  • Consider LALA mutations (as used with STI-9167 antibody) to prevent potential Fc-mediated enhancement of disease

  • Assess immunogenicity despite its human origin

• Clinical trial design challenges:

  • Rare and sporadic nature of ANDV outbreaks complicates trial recruitment

  • Ethical considerations around placebo controls for a lethal disease

  • Need for sensitive diagnostic assays to confirm ANDV infection rapidly

  • Defining appropriate clinical endpoints and biomarkers

• Regulatory considerations:

  • Orphan drug designation pathways

  • Emergency use authorization frameworks

  • Requirements for studies in special populations (pediatric, pregnant)

Addressing these challenges requires collaboration between academic researchers, industry partners, regulatory agencies, and clinical investigators specialized in emerging infectious diseases.

What potential exists for engineering bispecific antibodies incorporating JL16 binding domains?

Engineering bispecific antibodies incorporating JL16 binding domains offers several promising research directions:

• JL16-MIB22 bispecific formats:

  • Since these antibodies bind non-competitively to ANDV-GP, a bispecific combining both binding domains could provide enhanced protection

  • Format options include:

    • IgG-scFv fusions

    • Dual-variable domain immunoglobulins (DVD-Ig)

    • CrossMAb formats to ensure correct heavy/light chain pairing

• Cross-hantavirus targeting:

  • Create bispecifics targeting conserved epitopes across multiple hantaviruses

  • Combine JL16 with binding domains specific for other pathogenic hantaviruses (Sin Nombre virus, Puumala virus)

  • Develop pan-hantavirus therapeutics with broader protection spectrum

• Enhanced tissue targeting:

  • Engineer bispecifics with one arm targeting infected cells (via JL16) and another targeting tissue-specific markers

  • Improve delivery to infection sites in lungs and endothelial tissues

• Immune cell recruitment:

  • Develop T-cell engagers combining JL16 binding domains with anti-CD3

  • Create NK cell engagers using JL16 domains with anti-CD16

• Multivalent presentations:

  • Explore effects of avidity by creating antibodies with multiple JL16 binding domains

  • Test different linker lengths and geometries to optimize neutralization potency

These approaches should be evaluated not only for neutralization potency but also for manufacturability, stability, and immunogenicity profiles.

How might JL16 be incorporated into vaccine design strategies for ANDV?

JL16 could be incorporated into vaccine design strategies for ANDV in several innovative ways:

• Structure-based immunogen design:

  • Use structural information of JL16-ANDV-GP complex to design stabilized immunogens

  • Focus on presenting the JL16 epitope in an optimal conformation

  • Create scaffolded epitope presentations that mimic the native structure

• Sequential immunization approaches:

  • Design immunogen series to guide B-cell maturation toward JL16-like antibodies

  • Start with germline-targeting immunogens based on JL16's relatively high germline identity (91.12% heavy chain, 95.45% light chain)

  • Progressively introduce ANDV-specific features to induce affinity maturation

• Reverse vaccinology applications:

  • Analyze the key somatic hypermutations in JL16 that contribute to neutralization

  • Design immunogens specifically to elicit these critical mutations

  • This approach parallels strategies used for minimally mutated HIV broadly neutralizing antibodies

• Prime-boost strategies:

  • Use DNA vaccines encoding the JL16 epitope followed by protein boosts

  • Test heterologous vector systems (viral vectors, mRNA) to present epitopes

• Adjuvant optimization:

  • Identify adjuvants that promote antibody responses similar to JL16's isotype and subclass

  • Explore toll-like receptor agonists that favor neutralizing antibody development

These approaches could lead to vaccines that consistently elicit JL16-like antibodies across diverse genetic backgrounds in the population.

What novel technologies could enhance the delivery and efficacy of JL16 antibody therapies?

Novel technologies that could enhance JL16 delivery and efficacy include:

• Antibody half-life extension strategies:

  • Fc engineering to enhance FcRn binding and extend serum half-life

  • PEGylation or fusion to albumin-binding domains

  • Development of IgG-Fc fusion proteins

• Targeted delivery systems:

  • Antibody-drug conjugates targeting infected cells

  • Encapsulation in lung-targeting nanoparticles

  • Incorporation into inhalable formulations for direct pulmonary delivery

• Nucleic acid-based expression systems:

  • mRNA delivery systems encoding JL16 for in vivo expression

  • AAV-vectored antibody gene delivery for sustained expression

  • DNA plasmid delivery with electroporation for localized expression

• Combination with antiviral strategies:

  • Co-formulation with small molecule antivirals

  • Delivery with siRNAs targeting viral replication

  • Integration with immunomodulatory agents to enhance natural immunity

• Point-of-care administration technologies:

  • Development of stable liquid or lyophilized formulations

  • Creation of self-administered injection or inhalation devices

  • Intranasal delivery systems similar to those being developed for SARS-CoV-2 antibodies

These technological approaches could address challenges in remote settings where ANDV outbreaks occur and improve patient outcomes through enhanced bioavailability and simplified administration.

How can computational approaches predict JL16's efficacy against emerging ANDV strains?

Computational approaches can predict JL16's efficacy against emerging ANDV strains through:

• Molecular dynamics simulations:

  • Model JL16-ANDV-GP binding interactions under physiological conditions

  • Predict effects of glycoprotein mutations on binding energetics

  • Simulate antibody-epitope interactions at atomic resolution

• Machine learning algorithms:

  • Train ML models on existing neutralization data

  • Develop neural networks that predict neutralization sensitivity from sequence data

  • Apply deep learning to identify patterns in escape mutations

• Structural bioinformatics:

  • Create homology models of variant ANDV-GPs

  • Perform computational alanine scanning to identify critical binding residues

  • Use molecular docking to assess binding to variant epitopes

• Evolutionary analysis:

  • Apply phylogenetic methods to track ANDV evolution

  • Identify naturally occurring polymorphisms in JL16 epitope regions

  • Calculate selection pressure on epitope residues

• Network analysis approaches:

  • Map epitope conservation across hantavirus strains

  • Identify functional constraints on mutation of JL16 binding sites

  • Predict compensatory mutations that might arise with escape variants